SRNE vs. EVFM, NMTR, CYTO, UPC, PTEIQ, BIOR, PXMD, BDRX, PRFX, and TCBP
Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Evofem Biosciences (EVFM), 9 Meters Biopharma (NMTR), Altamira Therapeutics (CYTO), Universe Pharmaceuticals (UPC), PolarityTE (PTEIQ), Biora Therapeutics (BIOR), PaxMedica (PXMD), Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), and TC Biopharm (TCBP). These companies are all part of the "pharmaceutical products" industry.
Sorrento Therapeutics vs.
Evofem Biosciences (NASDAQ:EVFM) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.
In the previous week, Evofem Biosciences and Evofem Biosciences both had 1 articles in the media. Evofem Biosciences' average media sentiment score of 0.67 beat Sorrento Therapeutics' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media.
0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 0.2% of Evofem Biosciences shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sorrento Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Sorrento Therapeutics' return on equity of 0.00% beat Evofem Biosciences' return on equity.
Evofem Biosciences has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500.
Evofem Biosciences has higher earnings, but lower revenue than Sorrento Therapeutics.
Sorrento Therapeutics received 348 more outperform votes than Evofem Biosciences when rated by MarketBeat users. However, 69.50% of users gave Evofem Biosciences an outperform vote while only 68.46% of users gave Sorrento Therapeutics an outperform vote.
Summary
Sorrento Therapeutics beats Evofem Biosciences on 7 of the 12 factors compared between the two stocks.
Get Sorrento Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sorrento Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SRNE) was last updated on 1/21/2025 by MarketBeat.com Staff
